JP4563581B2 - フェノキシプロパノールアミン類、それらの製法及びそれらを含有する医薬組成物 - Google Patents
フェノキシプロパノールアミン類、それらの製法及びそれらを含有する医薬組成物 Download PDFInfo
- Publication number
- JP4563581B2 JP4563581B2 JP2000554720A JP2000554720A JP4563581B2 JP 4563581 B2 JP4563581 B2 JP 4563581B2 JP 2000554720 A JP2000554720 A JP 2000554720A JP 2000554720 A JP2000554720 A JP 2000554720A JP 4563581 B2 JP4563581 B2 JP 4563581B2
- Authority
- JP
- Japan
- Prior art keywords
- product
- mol
- group
- alk
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004519 manufacturing process Methods 0.000 title description 7
- 239000008194 pharmaceutical composition Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 101
- 238000000034 method Methods 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 25
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 125000006239 protecting group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 3
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 164
- 239000000047 product Substances 0.000 description 145
- 239000000203 mixture Substances 0.000 description 81
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- 239000002904 solvent Substances 0.000 description 51
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 40
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 35
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- -1 1- (pyrid-2-yl) -piperidin-4-yl groups Chemical group 0.000 description 32
- 239000007795 chemical reaction product Substances 0.000 description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 26
- 229960004592 isopropanol Drugs 0.000 description 25
- 238000010992 reflux Methods 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000002585 base Substances 0.000 description 19
- 238000004587 chromatography analysis Methods 0.000 description 17
- 238000003818 flash chromatography Methods 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 11
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- BYDXZYUGDXYSJY-UHFFFAOYSA-N 2-[(4-phenylmethoxyphenoxy)methyl]oxirane Chemical compound C1OC1COC(C=C1)=CC=C1OCC1=CC=CC=C1 BYDXZYUGDXYSJY-UHFFFAOYSA-N 0.000 description 4
- ZIJAZUBWHAZHPL-UHFFFAOYSA-N 6-chloropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=C(Cl)N=C1 ZIJAZUBWHAZHPL-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910006074 SO2NH2 Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- USSBDBZGEDUBHE-UHFFFAOYSA-L magnesium;2-oxidooxycarbonylbenzoate Chemical compound [Mg+2].[O-]OC(=O)C1=CC=CC=C1C([O-])=O USSBDBZGEDUBHE-UHFFFAOYSA-L 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- DVZURDNCUFYWGA-UHFFFAOYSA-N (3-methylsulfonyl-4-phenylmethoxyphenyl) benzoate Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(S(=O)(=O)C)=CC=1OC(=O)C1=CC=CC=C1 DVZURDNCUFYWGA-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WPVVMKYQOMJPIN-UHFFFAOYSA-N 1-(6-chloro-2-pyridinyl)-4-piperidinamine Chemical compound C1CC(N)CCN1C1=CC=CC(Cl)=N1 WPVVMKYQOMJPIN-UHFFFAOYSA-N 0.000 description 2
- LTENEPRDFSCUHJ-UHFFFAOYSA-N 4-[2-hydroxy-3-[[1-(5-nitropyridin-2-yl)piperidin-4-yl]amino]propoxy]phenol Chemical compound C=1C=C(O)C=CC=1OCC(O)CNC(CC1)CCN1C1=CC=C([N+]([O-])=O)C=N1 LTENEPRDFSCUHJ-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- UHYYTUZSQFSDOK-UHFFFAOYSA-N 6-[4-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]piperidin-1-yl]pyridine-3-carboxamide Chemical compound N1=CC(C(=O)N)=CC=C1N1CCC(NCC(O)COC=2C=CC(O)=CC=2)CC1 UHYYTUZSQFSDOK-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IRQSKJQDKUAART-UHFFFAOYSA-N methyl 6-(bromomethyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(CBr)N=C1 IRQSKJQDKUAART-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical class O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BYDXZYUGDXYSJY-INIZCTEOSA-N (2r)-2-[(4-phenylmethoxyphenoxy)methyl]oxirane Chemical compound C([C@@H]1OC1)OC(C=C1)=CC=C1OCC1=CC=CC=C1 BYDXZYUGDXYSJY-INIZCTEOSA-N 0.000 description 1
- ZKPFWJHJJVCVAJ-JGHKVMFLSA-N (2s)-2-[(3-methylsulfinyl-4-phenylmethoxyphenoxy)methyl]oxirane Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(S(=O)C)=CC=1OC[C@@H]1CO1 ZKPFWJHJJVCVAJ-JGHKVMFLSA-N 0.000 description 1
- BYDXZYUGDXYSJY-MRXNPFEDSA-N (2s)-2-[(4-phenylmethoxyphenoxy)methyl]oxirane Chemical compound C([C@H]1OC1)OC(C=C1)=CC=C1OCC1=CC=CC=C1 BYDXZYUGDXYSJY-MRXNPFEDSA-N 0.000 description 1
- RIHOYPLNDUTMND-UHFFFAOYSA-N (3-acetamido-4-phenylmethoxyphenyl) acetate Chemical compound CC(=O)NC1=CC(OC(C)=O)=CC=C1OCC1=CC=CC=C1 RIHOYPLNDUTMND-UHFFFAOYSA-N 0.000 description 1
- KQFVAFIKSQFLBX-UHFFFAOYSA-N (3-amino-4-phenylmethoxyphenyl) acetate Chemical compound NC1=CC(OC(=O)C)=CC=C1OCC1=CC=CC=C1 KQFVAFIKSQFLBX-UHFFFAOYSA-N 0.000 description 1
- LILQULQZZRFBDA-UHFFFAOYSA-N (3-bromo-4-phenylmethoxyphenyl) acetate Chemical compound BrC1=CC(OC(=O)C)=CC=C1OCC1=CC=CC=C1 LILQULQZZRFBDA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- LEXAYGVHWYOOAB-UHFFFAOYSA-N 1-(3-bromo-4-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC=C(O)C(Br)=C1 LEXAYGVHWYOOAB-UHFFFAOYSA-N 0.000 description 1
- YWUQUDYZGYDZLB-UHFFFAOYSA-N 1-(3-bromo-4-phenylmethoxyphenyl)ethanone Chemical compound BrC1=CC(C(=O)C)=CC=C1OCC1=CC=CC=C1 YWUQUDYZGYDZLB-UHFFFAOYSA-N 0.000 description 1
- ANWFNPNQSGHEAZ-UHFFFAOYSA-N 1-(3-ethoxy-2,4-dimethoxyphenoxy)-3-[[1-(5-nitropyridin-2-yl)piperidin-4-yl]amino]propan-2-ol Chemical compound CCOC1=C(C=CC(=C1OC)OCC(CNC2CCN(CC2)C3=NC=C(C=C3)[N+](=O)[O-])O)OC ANWFNPNQSGHEAZ-UHFFFAOYSA-N 0.000 description 1
- RJIWXUKKULIFHJ-UHFFFAOYSA-N 1-(5-chloropyridin-2-yl)piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=C(Cl)C=N1 RJIWXUKKULIFHJ-UHFFFAOYSA-N 0.000 description 1
- QQEOMBKEYFJWMG-UHFFFAOYSA-N 1-(5-methylpyridin-2-yl)piperidin-4-amine Chemical compound N1=CC(C)=CC=C1N1CCC(N)CC1 QQEOMBKEYFJWMG-UHFFFAOYSA-N 0.000 description 1
- UXNGJVZEAQGYOA-UHFFFAOYSA-N 1-(5-nitropyridin-2-yl)piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=C([N+]([O-])=O)C=N1 UXNGJVZEAQGYOA-UHFFFAOYSA-N 0.000 description 1
- MHKZEPLHUMBAES-UHFFFAOYSA-N 1-(pyridin-2-ylmethyl)piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=N1 MHKZEPLHUMBAES-UHFFFAOYSA-N 0.000 description 1
- XOBJSIQMOWXPAE-UHFFFAOYSA-N 1-[2-hydroxy-5-(oxiran-2-ylmethoxy)phenyl]ethanone Chemical compound C1=C(O)C(C(=O)C)=CC(OCC2OC2)=C1 XOBJSIQMOWXPAE-UHFFFAOYSA-N 0.000 description 1
- UASDZTUTGBHWJG-UHFFFAOYSA-N 1-[5-(oxiran-2-ylmethoxy)-2-phenylmethoxyphenyl]ethanone Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(C(=O)C)=CC=1OCC1CO1 UASDZTUTGBHWJG-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- CZINLSYKXBADTA-UHFFFAOYSA-N 1-pyridin-2-ylpiperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC=N1 CZINLSYKXBADTA-UHFFFAOYSA-N 0.000 description 1
- WLDWSGZHNBANIO-UHFFFAOYSA-N 2',5'-Dihydroxyacetophenone Chemical compound CC(=O)C1=CC(O)=CC=C1O WLDWSGZHNBANIO-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- GJYHWMPDENJDNT-UHFFFAOYSA-N 2-[(3-bromo-4-phenylmethoxyphenoxy)methyl]oxirane Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(Br)=CC=1OCC1CO1 GJYHWMPDENJDNT-UHFFFAOYSA-N 0.000 description 1
- GOPLTCTUEOUNSP-UHFFFAOYSA-N 2-[(3-methylsulfonyl-4-phenylmethoxyphenoxy)methyl]oxirane Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(S(=O)(=O)C)=CC=1OCC1CO1 GOPLTCTUEOUNSP-UHFFFAOYSA-N 0.000 description 1
- CRXTZLKUJSMSEL-UHFFFAOYSA-N 2-[[4-[ethoxy(methoxy)methoxy]phenoxy]methyl]oxirane Chemical compound C1=CC(OC(OC)OCC)=CC=C1OCC1OC1 CRXTZLKUJSMSEL-UHFFFAOYSA-N 0.000 description 1
- BZUUVQCSPHPUQA-UHFFFAOYSA-N 2-bromo-5-chloropyridine Chemical compound ClC1=CC=C(Br)N=C1 BZUUVQCSPHPUQA-UHFFFAOYSA-N 0.000 description 1
- YWNJQQNBJQUKME-UHFFFAOYSA-N 2-bromo-5-methylpyridine Chemical compound CC1=CC=C(Br)N=C1 YWNJQQNBJQUKME-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
- QXCOHSRHFCHCHN-UHFFFAOYSA-N 2-chloropyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(Cl)=C1 QXCOHSRHFCHCHN-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QYFWQQWXNPVUPS-UHFFFAOYSA-N 4-[2-hydroxy-3-[(1-pyridin-2-ylpiperidin-4-yl)amino]propoxy]phenol Chemical compound C=1C=C(O)C=CC=1OCC(O)CNC(CC1)CCN1C1=CC=CC=N1 QYFWQQWXNPVUPS-UHFFFAOYSA-N 0.000 description 1
- ZTBBDJDYGPRPIW-UHFFFAOYSA-N 4-[2-hydroxy-3-[[1-(5-methylpyridin-2-yl)piperidin-4-yl]amino]propoxy]phenol Chemical compound N1=CC(C)=CC=C1N1CCC(NCC(O)COC=2C=CC(O)=CC=2)CC1 ZTBBDJDYGPRPIW-UHFFFAOYSA-N 0.000 description 1
- IOYGHHMSPCCGMI-UHFFFAOYSA-N 4-[2-hydroxy-3-[[1-(pyridin-2-ylmethyl)piperidin-4-yl]amino]propoxy]phenol Chemical compound C=1C=C(O)C=CC=1OCC(O)CNC(CC1)CCN1CC1=CC=CC=N1 IOYGHHMSPCCGMI-UHFFFAOYSA-N 0.000 description 1
- HDFPSVQVBQHETC-UHFFFAOYSA-N 4-[3-[[1-(5-chloropyridin-2-yl)piperidin-4-yl]amino]-2-hydroxypropoxy]phenol Chemical compound C=1C=C(O)C=CC=1OCC(O)CNC(CC1)CCN1C1=CC=C(Cl)C=N1 HDFPSVQVBQHETC-UHFFFAOYSA-N 0.000 description 1
- JZNCELCXZONBCM-UHFFFAOYSA-N 4-[3-[[1-(6-chloropyridin-2-yl)piperidin-4-yl]amino]-2-hydroxypropoxy]phenol Chemical compound C=1C=C(O)C=CC=1OCC(O)CNC(CC1)CCN1C1=CC=CC(Cl)=N1 JZNCELCXZONBCM-UHFFFAOYSA-N 0.000 description 1
- YCJMDLIMUBMVRG-UHFFFAOYSA-N 6-(4-aminopiperidin-1-yl)pyridine-3-carbonitrile Chemical group C1CC(N)CCN1C1=CC=C(C#N)C=N1 YCJMDLIMUBMVRG-UHFFFAOYSA-N 0.000 description 1
- IBFVCMAHXVYHFQ-UHFFFAOYSA-N 6-(4-aminopiperidin-1-yl)pyridine-3-carboxamide Chemical compound C1CC(N)CCN1C1=CC=C(C(N)=O)C=N1 IBFVCMAHXVYHFQ-UHFFFAOYSA-N 0.000 description 1
- CYFXRKFHYCXDDU-UHFFFAOYSA-N 6-[4-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]piperidin-1-yl]pyridine-3-carbonitrile Chemical compound C=1C=C(O)C=CC=1OCC(O)CNC(CC1)CCN1C1=CC=C(C#N)C=N1 CYFXRKFHYCXDDU-UHFFFAOYSA-N 0.000 description 1
- PDJZWZQJVDYIET-UHFFFAOYSA-N 6-[4-[[2-hydroxy-3-(4-phenylmethoxyphenoxy)propyl]amino]piperidin-1-yl]pyridine-3-carboxamide Chemical compound N1=CC(C(=O)N)=CC=C1N1CCC(NCC(O)COC=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 PDJZWZQJVDYIET-UHFFFAOYSA-N 0.000 description 1
- ZLKMOIHCHCMSFW-UHFFFAOYSA-N 6-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Cl)=N1 ZLKMOIHCHCMSFW-UHFFFAOYSA-N 0.000 description 1
- ORIQLMBUPMABDV-UHFFFAOYSA-N 6-chloropyridine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)C=N1 ORIQLMBUPMABDV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- PKJRKAHYPSGZLZ-UHFFFAOYSA-N N1=CC(C)=CC=C1N1CCC(NCC(O)COC=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 Chemical compound N1=CC(C)=CC=C1N1CCC(NCC(O)COC=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 PKJRKAHYPSGZLZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000342 anti-suppressant effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- GJARTKJVJAPDOR-UHFFFAOYSA-N ethyl 2-(4-aminopiperidin-1-yl)pyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(N2CCC(N)CC2)=C1 GJARTKJVJAPDOR-UHFFFAOYSA-N 0.000 description 1
- ZZLQHKITNKFKKA-UHFFFAOYSA-N ethyl 2-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]piperidin-1-yl]pyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(N2C(CCCC2)NCC(O)COC=2C=CC(O)=CC=2)=C1 ZZLQHKITNKFKKA-UHFFFAOYSA-N 0.000 description 1
- KOGNOKSIBUTYEA-UHFFFAOYSA-N ethyl 6-(4-aminopiperidin-1-yl)pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC(N2CCC(N)CC2)=N1 KOGNOKSIBUTYEA-UHFFFAOYSA-N 0.000 description 1
- ZLZGWYCDEZAFBU-UHFFFAOYSA-N ethyl 6-(4-aminopiperidin-1-yl)pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OCC)=CC=C1N1CCC(N)CC1 ZLZGWYCDEZAFBU-UHFFFAOYSA-N 0.000 description 1
- FWXRDEVSDCJSHB-UHFFFAOYSA-N ethyl 6-[4-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]piperidin-1-yl]pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC(N2CCC(CC2)NCC(O)COC=2C=CC(O)=CC=2)=N1 FWXRDEVSDCJSHB-UHFFFAOYSA-N 0.000 description 1
- GHIDWIOGIVBYRA-UHFFFAOYSA-N ethyl 6-[4-[[2-hydroxy-3-(4-phenylmethoxyphenoxy)propyl]amino]piperidin-1-yl]pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC(N2CCC(CC2)NCC(O)COC=2C=CC(OCC=3C=CC=CC=3)=CC=2)=N1 GHIDWIOGIVBYRA-UHFFFAOYSA-N 0.000 description 1
- CTOTYLRNRSAPFU-UHFFFAOYSA-N ethyl 6-[4-[[3-[3-(furan-2-yl)-4-hydroxyphenoxy]-2-hydroxypropyl]amino]piperidin-1-yl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OCC)=CC=C1N1CCC(NCC(O)COC=2C=C(C(O)=CC=2)C=2OC=CC=2)CC1 CTOTYLRNRSAPFU-UHFFFAOYSA-N 0.000 description 1
- ORSVWYSFUABOQU-UHFFFAOYSA-N ethyl 6-chloropyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC(Cl)=N1 ORSVWYSFUABOQU-UHFFFAOYSA-N 0.000 description 1
- ILDJJTQWIZLGPO-UHFFFAOYSA-N ethyl 6-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(Cl)N=C1 ILDJJTQWIZLGPO-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- UUBJKHVFGWGJKX-UHFFFAOYSA-N hydrate tetrahydrochloride Chemical compound O.Cl.Cl.Cl.Cl UUBJKHVFGWGJKX-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- XJOUOTHJMRWHKL-UHFFFAOYSA-N methyl 6-[(4-aminopiperidin-1-yl)methyl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1CN1CCC(N)CC1 XJOUOTHJMRWHKL-UHFFFAOYSA-N 0.000 description 1
- FAAJRQDPLMDQRN-UHFFFAOYSA-N methyl 6-[[4-(aminomethyl)piperidin-1-yl]methyl]pyridine-3-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=CC(C(=O)OC)=CC=C1CN1CCC(CN)CC1 FAAJRQDPLMDQRN-UHFFFAOYSA-N 0.000 description 1
- YMAIRDRJTVOADI-UHFFFAOYSA-N methyl 6-[[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]piperidin-1-yl]methyl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1CN1CCC(CNC(=O)OC(C)(C)C)CC1 YMAIRDRJTVOADI-UHFFFAOYSA-N 0.000 description 1
- BZQOKLQAZVAORE-UHFFFAOYSA-N methyl 6-[[4-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]piperidin-1-yl]methyl]pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1CN1CCC(NCC(O)COC=2C=CC(O)=CC=2)CC1 BZQOKLQAZVAORE-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- FPFKVOAWSPXBCM-UHFFFAOYSA-N n-(5-hydroxy-2-phenylmethoxyphenyl)acetamide Chemical compound CC(=O)NC1=CC(O)=CC=C1OCC1=CC=CC=C1 FPFKVOAWSPXBCM-UHFFFAOYSA-N 0.000 description 1
- WOMXPFICXRGWHL-UHFFFAOYSA-N n-[1-(5-chloropyridin-2-yl)piperidin-4-yl]acetamide Chemical compound C1CC(NC(=O)C)CCN1C1=CC=C(Cl)C=N1 WOMXPFICXRGWHL-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YLWUSMHZABTZGP-UHFFFAOYSA-N n-piperidin-4-ylacetamide Chemical compound CC(=O)NC1CCNCC1 YLWUSMHZABTZGP-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- AAVIRJCSXRCHJF-UHFFFAOYSA-N tert-butyl n-[1-(5-carbamoylpyridin-2-yl)piperidin-4-yl]carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1C1=CC=C(C(N)=O)C=N1 AAVIRJCSXRCHJF-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9807660A FR2780057B1 (fr) | 1998-06-18 | 1998-06-18 | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR98/07660 | 1998-06-18 | ||
| PCT/FR1999/001370 WO1999065895A1 (fr) | 1998-06-18 | 1999-06-10 | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002518385A JP2002518385A (ja) | 2002-06-25 |
| JP2002518385A5 JP2002518385A5 (enExample) | 2010-05-06 |
| JP4563581B2 true JP4563581B2 (ja) | 2010-10-13 |
Family
ID=9527517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000554720A Expired - Fee Related JP4563581B2 (ja) | 1998-06-18 | 1999-06-10 | フェノキシプロパノールアミン類、それらの製法及びそれらを含有する医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6649627B1 (enExample) |
| EP (1) | EP1087961B1 (enExample) |
| JP (1) | JP4563581B2 (enExample) |
| AR (1) | AR018639A1 (enExample) |
| AT (1) | ATE222250T1 (enExample) |
| AU (1) | AU4048299A (enExample) |
| CO (1) | CO5011052A1 (enExample) |
| DE (1) | DE69902535T2 (enExample) |
| ES (1) | ES2183557T3 (enExample) |
| FR (1) | FR2780057B1 (enExample) |
| GT (1) | GT199900102A (enExample) |
| WO (1) | WO1999065895A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| AU2525801A (en) | 1999-12-17 | 2001-06-25 | Sanofi-Synthelabo | Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them |
| FR2802533B1 (fr) * | 1999-12-17 | 2002-02-15 | Sanofi Synthelabo | Phenoxypropanolamines, leur preparation et leur application en therapeutique |
| CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
| US6753322B2 (en) | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
| US7005439B2 (en) | 2000-06-20 | 2006-02-28 | Astrazeneca Ab | Compounds |
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| HUP0301329A2 (hu) * | 2000-07-13 | 2003-08-28 | Eli Lilly And Co. | Béta3 Adrenergiás agonisták, valamint ezen vegyületeket tartalmazó gyógyászati készítmények és eljárás e vegyületek előállítására |
| US6506901B2 (en) * | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6458817B1 (en) | 2000-07-17 | 2002-10-01 | Wyeth | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists |
| US6444685B1 (en) * | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
| US6395762B1 (en) | 2000-07-17 | 2002-05-28 | American Home Products Corporation | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6514991B2 (en) | 2000-07-17 | 2003-02-04 | Wyeth | Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists |
| US6498170B2 (en) * | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6509358B2 (en) | 2000-07-17 | 2003-01-21 | Wyeth | Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
| FR2817257B1 (fr) | 2000-11-30 | 2009-03-20 | Sanofi Synthelabo | Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant |
| GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| AR035230A1 (es) | 2001-03-19 | 2004-05-05 | Astrazeneca Ab | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| SE0101038D0 (sv) * | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| HUP0200849A2 (hu) * | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| FR2840301B1 (fr) * | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
| SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
| ES2691646T3 (es) | 2005-07-15 | 2018-11-28 | Micell Technologies, Inc. | Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada |
| TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
| HRP20120494T1 (hr) | 2006-04-21 | 2012-08-31 | Novartis Ag | Derivati purina za uporabu kao agonista adenozin a2a receptora |
| CA2996768C (en) | 2006-04-26 | 2020-12-08 | Micell Technologies, Inc. | Coatings containing multiple drugs |
| WO2008042909A2 (en) | 2006-10-02 | 2008-04-10 | Micell Technologies Inc. | Surgical sutures having increased strength |
| JP5336382B2 (ja) | 2006-10-23 | 2013-11-06 | ミセル テクノロジーズ、インコーポレイテッド | コーティングの間に基板を荷電するためのホルダー |
| CN101711137B (zh) | 2007-01-08 | 2014-10-22 | 米歇尔技术公司 | 具有可生物降解层的支架 |
| US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| CN101815540B (zh) | 2007-05-25 | 2015-08-19 | 米歇尔技术公司 | 用于医疗器材涂层的聚合物膜 |
| CA2721832C (en) | 2008-04-17 | 2018-08-07 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
| WO2010009335A1 (en) | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
| US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
| CN102481195B (zh) | 2009-04-01 | 2015-03-25 | 米歇尔技术公司 | 涂覆支架 |
| EP3366326A1 (en) | 2009-04-17 | 2018-08-29 | Micell Technologies, Inc. | Stents having controlled elution |
| EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | MEDICAL DEVICE DISPENSING MEDICINE |
| EP2531140B1 (en) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
| US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
| WO2011133655A1 (en) | 2010-04-22 | 2011-10-27 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
| WO2012009684A2 (en) | 2010-07-16 | 2012-01-19 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2012166819A1 (en) | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
| US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
| US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| CN110269959A (zh) | 2013-03-12 | 2019-09-24 | 脉胜医疗技术公司 | 可生物吸收的生物医学植入物 |
| WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
| MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI76551C (fi) * | 1980-11-06 | 1988-11-10 | Sandoz Ag | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-aminopropoxifenylderivat. |
| JPS6137765A (ja) * | 1984-07-19 | 1986-02-22 | サンド・アクチエンゲゼルシヤフト | ３‐アミノプロポキシアリール誘導体 |
| GB2163150B (en) * | 1984-07-19 | 1988-05-25 | Sandoz Ltd | 3-aminopropoxyaryl derivatives |
| FR2620704B1 (fr) * | 1987-09-17 | 1991-04-26 | Sanofi Sa | Derives de (benzyl-4 piperidino)-1 propanol-2, leur preparation, leur utilisation comme antimicrobiens et les produits les contenant |
| ATE117980T1 (de) * | 1988-06-03 | 1995-02-15 | Lilly Co Eli | Serotonin-antagonisten. |
| FR2640969B1 (enExample) * | 1988-12-23 | 1991-11-22 | Midy Spa | |
| US5145967A (en) * | 1989-04-20 | 1992-09-08 | Anaquest, Inc. | Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof |
| US5340160A (en) | 1989-11-21 | 1994-08-23 | Wavin B.V. | Thermoplastic saddle in two parts for repairing or renovating a pipe line with branch pipe and repaired or renovated pipe with a saddle |
| DE69228017D1 (de) * | 1991-03-27 | 1999-02-11 | Sanofi Sa | Verwendung von 4-Amino-1-(2-Pyridyl)Piperidinen als 5-HT3-Agonisten zur Behandlung und Verhütung von serotoninergen Dysfunktionen |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| GB9318431D0 (en) * | 1993-09-06 | 1993-10-20 | Boots Co Plc | Therapeutic agents |
| US5502063A (en) * | 1993-10-11 | 1996-03-26 | Sanofi | 1-halopyridin-4-amino-4-alkylpiperidines |
-
1998
- 1998-06-18 FR FR9807660A patent/FR2780057B1/fr not_active Expired - Fee Related
-
1999
- 1999-06-04 CO CO99035290A patent/CO5011052A1/es unknown
- 1999-06-09 AR ARP990102731A patent/AR018639A1/es unknown
- 1999-06-10 DE DE69902535T patent/DE69902535T2/de not_active Expired - Lifetime
- 1999-06-10 ES ES99923710T patent/ES2183557T3/es not_active Expired - Lifetime
- 1999-06-10 WO PCT/FR1999/001370 patent/WO1999065895A1/fr not_active Ceased
- 1999-06-10 JP JP2000554720A patent/JP4563581B2/ja not_active Expired - Fee Related
- 1999-06-10 AT AT99923710T patent/ATE222250T1/de not_active IP Right Cessation
- 1999-06-10 US US09/719,640 patent/US6649627B1/en not_active Expired - Fee Related
- 1999-06-10 AU AU40482/99A patent/AU4048299A/en not_active Abandoned
- 1999-06-10 EP EP99923710A patent/EP1087961B1/fr not_active Expired - Lifetime
- 1999-07-01 GT GT199900102A patent/GT199900102A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2780057A1 (fr) | 1999-12-24 |
| GT199900102A (es) | 2000-12-22 |
| DE69902535T2 (de) | 2003-04-10 |
| WO1999065895A1 (fr) | 1999-12-23 |
| EP1087961A1 (fr) | 2001-04-04 |
| FR2780057B1 (fr) | 2002-09-13 |
| CO5011052A1 (es) | 2001-02-28 |
| JP2002518385A (ja) | 2002-06-25 |
| ATE222250T1 (de) | 2002-08-15 |
| DE69902535D1 (de) | 2002-09-19 |
| AR018639A1 (es) | 2001-11-28 |
| ES2183557T3 (es) | 2003-03-16 |
| US6649627B1 (en) | 2003-11-18 |
| EP1087961B1 (fr) | 2002-08-14 |
| AU4048299A (en) | 2000-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6649627B1 (en) | Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same | |
| DE60012048T2 (de) | Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung | |
| US6867220B2 (en) | Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them | |
| EP0863136B1 (en) | Derivatives of azetidine and pyrrolidine | |
| KR100523184B1 (ko) | 아제티딘 및 피롤리딘의 유도체 | |
| JPH04154737A (ja) | 神経細胞変性修復又は保護剤 | |
| SK129590A3 (en) | 3-substituted pyrolidine derivative, preparation method thereof, intermediate products of this method, pharmaceutical composition containing this derivative | |
| EP0168505B1 (en) | Substituted 2-aminotetralins and processes for synthesis | |
| HUT77520A (hu) | Neuroprotektív hatású kromán-4,7-diol- és 1-(4-hidroxifenil)-alkanol-származékok és azokat hatóanyagként tartalmazó gyógyszerkészítmények | |
| JP2006516271A (ja) | ナトリウム／カルシウム交換系の阻害に有用なピリジン誘導体 | |
| DE60011916T2 (de) | Heteroaryloxypropanolamine als beta3-adrenergischer rezeptor-agonisten | |
| EP1635828B1 (en) | 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors | |
| WO2005040093A1 (ja) | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 | |
| US20080132710A1 (en) | Atrasentan hydrochloride crystalline form 2 | |
| EP0505465B1 (en) | 4-Heterocyclyl-piperidine derivatives, their preparation and their use as inhibitors of calcium overload in brain cells | |
| DE60102084T2 (de) | Propanolaminotetraline, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| KR20050119682A (ko) | 세로토닌 재흡수 억제제로서 4-(2-페닐옥시페닐)-피페리딘또는 -1,2,3,6-테트라히드로피리딘 유도체 | |
| MXPA00008387A (en) | Derivatives of azetidine and pyrrolidine | |
| HK1010881B (en) | Derivatives of azetidine and pyrrolidine | |
| CS205086B2 (cs) | Způsob výroby hydroxyderivátů aryloxy- a arylthioperhydroazaheterocyklů | |
| WO2001025202A1 (en) | Process for the preparation of paroxetine intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060608 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060608 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091215 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20100311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100312 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100406 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100617 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100713 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100729 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130806 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |